New drugs and indications in 2014. Some advances this year, but many drugs are poorly evaluated, too expensive, or more dangerous than useful.
Three drugs analysed by Prescrire in 2014 provided a significant therapeutic advance for some patients. In 2014, too many drugs are still best avoided, have undergone minimal evaluation, or are excessively expensive. Drug regulatory agencies should continue their efforts to improve pharmacovigilance and transparency.